Symposium:
111. Susceptibility Breakpoints Controversies and Consensus
Saturday, October 23, 2010: 10:30 AM-12:00 PM
Parkview Terrace / 1-3

Learning Objectives:

After completion of this session, the participant should be able to:

  • describe the recent changes in approach to development of susceptibility breakpoints
  • review the controversies and common ground with regard to breakpoint development from the perspective of the Food and Drug Administration (FDA), Clinical and Laboratory Standards Institute (CLSI), and pharmaceutical industry
  • discuss how the recent susceptibility breakpoint changes may impact clinical practice and drug development

Target Audience: Scientists, Researchers, Pharmacists, Microbiologists, Lab Personnel, Investigators, Infectious Disease Physicians, Hospital Epidemiologists, Health Care Workers, Fellows-in-Training/Fellows, Epidemiologists, Clinicians, Academicians

Topical Category: A. Antimicrobial agents and Resistance

Tracks: Investigative ID, Pediatric ID, Adult ID

CME Credits: CME Maximum of 1.5 hours of Category 1 credit possible - CREDIT APPROVED

ACPE Credits: No Pharmacy CE credit possible

ACPE Number: N/A

Moderators:  Sujata Bhavnani, PharmD, M.S., Institute for Clinical Pharmacodynamics and David Andes, MD, University of Wisconsin Hospital

Disclosures:

S. Bhavnani, Yes
Achaogen: Grant Investigator, Research grant
Astellas: Grant Investigator, Research grant
Bristol-Myers Squibb: Grant Investigator, Research grant
Cempra : Grant Investigator, Research grant
Cerexa: Grant Investigator, Research grant
Cubist: Grant Investigator, Research grant
IASO Pharma: Grant Investigator, Research grant
The Medicines Company: Grant Investigator, Research grant
Mpex: Grant Investigator, Research grant
Nabriva: Grant Investigator, Research grant
Novartis: Grant Investigator, Research grant
Pfizer: Consultant, Research grant
Rib-X: Grant Investigator, Research grant
Roche: Grant Investigator, Research grant
Transave: Grant Investigator, Research grant
PolyMedix: Grant Investigator, Research grant
Protez: Grant Investigator, Research grant

D. Andes, Yes
Astellas: Grant Investigator, Research grant
Merck: Consultant and Grant Investigator, Consulting fee and Grant recipient
Pfizer: Consultant, Consulting fee

Presentations:

10:30 AM
854
FDA
Katherine Laessig, MD


11:30 AM
856
Industry
Glenn Tillotson, PhD, FIDSA
See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 21 with the exception of research findings presented at IDSA press conferences.

 
 
   
 

Copyright IDSA 2009 Infectious Diseases Society of America 1300 Wilson Boulevard, Suite 300 Arlington, VA 22209 info@idsociety.org